At UCI Health, leading oncologists specialize in the latest treatment options for HER2-positive metastatic breast cancer, including Kisqali. The medical center is known for its advanced …

Kisqali can extend survival and the amount of time you live without HR+/HER2- advanced or metastatic breast cancer getting worse, as part of a combination treatment regimen. In pre- …

Learn about HR+, HER2- metastatic breast cancer treatment in premenopausal and postmenopausal women with KISQALI. See full Prescribing & Safety Info.

Indications KISQALI is indicated for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast …

In younger women with advanced breast cancer, ribociclib (Kisqali) plus hormone therapy shrank metastatic tumors better than standard chemotherapy treatments.

How Well Does Kisqali Work for Breast Cancer? The FDA approved Kisqali for HR-positive, HER2-negative metastatic breast cancer based on multiple clinical trials.

Explore innovative treatments for HER2-positive breast cancer, including Kisqali Pi, targeted therapies, immunotherapy, and tips for managing side effects and living with metastatic breast …

Further, Kisqali in combination with either letrozole or fulvestrant has uniquely, among other CDK4/6 inhibitors, received a score of four out of five for post-menopausal patients with …

Kisqali (ribociclib) is a prescription medicine used to treat a type of breast cancer called HR+/HER2- (hormone receptor-positive/human epidermal growth factor receptor 2-negative) …

KISQALI is a prescription medicine used to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has gotten …